NLRP3 Inhibitors

JT002, a small molecule inhibitor of the NLRP3 inflammasome for ...

JT002 potently reduced NLRP3-dependent proinflammatory cytokine production across a number of cellular assays and prevented pyroptosis.

Recent Progress and Prospects of Small Molecules for NLRP3 ...

Natural products are an important source of NLRP3 inflammasome inhibitors. Natural molecules, such as oridonin, (132) glycyrrhizin, (155) and ...

Inhibitors of the NLRP3 inflammasome pathway as promising ...

The aberrant activation of the NLRP3 inflammasome has been linked to various inflammatory diseases, including atherosclerosis, ischemic stroke, Alzheimer's ...

Pharmacological Inhibitors of the NLRP3 Inflammasome - Frontiers

This paper will review the various pharmacological inhibitors of the NLRP3 inflammasome and will also discuss their mechanism of action.

NLRP3 inhibitors: Unleashing their therapeutic potential against ...

The development of NLRP3 inflammasome inhibitors are viable option for the treatment of diverse inflammatory disorders.

NodThera's NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of ...

Taken together, the findings demonstrate that NT-0796 successfully delivered anti-inflammatory changes in an obese inflamed population, ...

NLRP3 inflammasome and its inhibitors: a review - PMC

Like MCC950, BHB appears to block inflammasome activation by inhibiting NLRP3-induced ASC oligomerization. Their in vivo experiments showed that BHB or a ...

NLRP3 - Ventus Therapeutics

NLRP3 · Aberrant activation of the NLRP3 inflammasome is a key driver in many diseases · Validation of the NLRP3 pathway · VENT-01, an oral systemic inhibitor of ...

Recent advances in the mechanisms of NLRP3 inflammasome ...

A small-molecule inhibitor of the NLRP3 inflammasome termed MCC950 was described by Coll et al. in 2015. MCC950 specifically inhibits both ...

NLRP3 inflammasome inhibitor - MCC950 - InvivoGen

MCC950 (CP-456773) is a potent and selective inhibitor of the NLRP3 inflammasome. MCC950, CAS 210826-40-7, from InvivoGen is tested in cell culture for ...

Interrogating direct NLRP3 engagement and functional ...

Utilizing these complementary assays, we confirm that oridonin, NBC6, NBC19, and CY-09 are direct NLRP3 inhibitors. They block binding of an NLRP3 specific ...

Novel chemotype NLRP3 inhibitors that target the CRID3-binding ...

We describe a novel chemical class of NLRP3-inhibiting compounds (NIC) that exhibit potent and selective NLRP3 inflammasome inhibition in human monocytes and ...

Discovery and Development of NLRP3 Inhibitors Targeting the LRR ...

These findings introduce novel small molecule inhibitors targeting the LRR domain of NLRP3 protein and disrupt NLRP3-NEK7 interaction, offering a novel ...

Screening NLRP3 drug candidates in clinical development - Frontiers

Since NLRP3 inhibitors suppress parts of the immune response, there is a theoretical risk of increased susceptibility to infections. However, ...

Arachidonic acid inhibition of the NLRP3 inflammasome is a ...

Arachidonic acid inhibition of the NLRP3 inflammasome is a mechanism to explain the anti-inflammatory effects of fasting.

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure ...

NLRP3 inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease.

Spotlight on Clinical NLRP3 Inflammasome Inhibitors

Several specific inflammasome inhibitors that have entered the clinic are briefly reviewed below, although clinical data from them is not always accessible.

Full article: Repurposing FDA-approved drugs as NLRP3 inhibitors ...

The present study was aimed at repurposing preexisting drugs that might act as safe and effective NLRP3 inhibitors.

Brazilin is a natural product inhibitor of the NLRP3 inflammasome

Brazilin inhibits the activation step of the canonical NLRP3 inflammasome. As discussed previously, the NLRP3 inflammasome can be activated by a range of DAMPs ...

NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug ... - MDPI

Several types of NLRP3 inhibitors have been developed and their effect has been validated both in in vitro and in vivo models of epileptogenesis.